RayKnowChina Research Map
Shortlist0

Soochow University

苏州大学

SuzhouUniversity or health system

Hospitals that carry this university's name, added together, plus papers and trials that name only the university.

Research activity, not treatment quality. Not medical advice. How this works

Nasopharyngeal carcinoma

鼻咽癌
0.8%Leads under 1 in 100 of China's research papers on NPC

Led 18 of 2,375 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.4%).

Run this PubMed search

Open trials led
0
Research papers it led
18
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 3320242025: 002025
ThemesRadiotherapy techniqueInduction / concurrent chemotherapyImaging & AI

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. First Affiliated Hospital of Soochow University8
  2. Second Affiliated Hospital of Soochow University5
  3. Third Affiliated Hospital of Soochow University1
  4. Changzhou Cancer Hospital, Soochow University1
  5. Second Affiliate Hospital, Soochow University1
  6. Children Hospital, Soochow University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Oesophageal squamous cell carcinoma

食管鳞状细胞癌
1.4%Leads about 1 in 71 of China's research papers on ESCC

Led 41 of 2,923 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.9%).

Run this PubMed search

Open trials led
0
Research papers it led
41
Trials it led
2
Share of China's trials
0.4%
Share of the world's papers
0.9%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 332025
ThemesMolecular markers & genomicsImaging & AIImmunotherapy

Hospitals counted here

  1. First Affiliated Hospital of Soochow University22
  2. Third Affiliated Hospital of Soochow University9
  3. Second Affiliated Hospital of Soochow University4
  4. Fourth Affiliated Hospital of Soochow University Counted in the group total2
  5. Dushu Lake Hospital, Soochow University Counted in the group total1
  6. Affiliated Infectious Diseases Hospital of Suzhou Medical College of Soochow University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Prognostic implications of microRNA-107 in esophageal cancer: a retrospective cohort study.2025PeerJFree full text
  2. Correlation of immune cell subsets in the tumor microenvironment and peripheral blood with immunotherapy response in esophageal squamous cell carcinoma.2025Frontiers in immunologyFree full text
  3. Multimodal deep learning for predicting PD-L1 biomarker and clinical immunotherapy outcomes of esophageal cancer.2025Frontiers in immunologyFree full text
  4. Integrating 18F-FDG PET/CT radiomics and body composition for enhanced prognostic assessment in patients with esophageal cancer.2024BMC cancerFree full text
  5. Diagnostic Efficacy of Type B Vessels in the Japan Esophageal Society Classification for the Depth of Invasion of Superficial Esophageal Squamous Cell Carcinoma.2024Annali italiani di chirurgia
Trials on ClinicalTrials.gov6
  1. Correlation Between the Efficacy of Neoadjuvant Chemotherapy Combined With Immunotherapy of Operable Thoracic Esophageal Squamous Cell Carcinoma and the Metabolites of Intestinal FloraStatus unknownNCT05199649Lead sponsorN/AStart 2021-12
  2. Effectiveness of Neoadjuvant Chemotherapy Combined With PD-1 Monoclonal Antibody in the Treatment of Operable Esophageal Squamous Cell CarcinomaStatus unknownNCT05174325Lead sponsorPhase 2Start 2020-12
  3. A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT06010303Study sitePhase 2Start 2023-11
  4. Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT04732494Study sitePhase 2Start 2021-03
  5. A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell CarcinomaCompletedNCT03430843Study sitePhase 3Start 2018-01
  6. A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell CarcinomaCompletedNCT03783442Study sitePhase 3Start 2018-12

PubMed searchClinicalTrials.gov

Hepatocellular carcinoma

肝细胞癌
0.9%Leads under 1 in 100 of China's research papers on HCC

Led 135 of 14,765 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (5.5%).

Run this PubMed search

Open trials led
0
Research papers it led
135
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 1120242025: 222025
ThemesImaging, AI & early detectionRecurrence & prognosisLocal treatment (ablation, TACE, HAIC)

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. First Affiliated Hospital of Soochow University73
  2. Third Affiliated Hospital of Soochow University17
  3. Second Affiliated Hospital of Soochow University Counted in the group total11
  4. Fourth Affiliated Hospital of Soochow University Counted in the group total8
  5. Dushu Lake Hospital, Soochow University Counted in the group total4
  6. Affiliated Hospital of Soochow University Counted in the group total3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Analysis of common treatment-related adverse events of donafenib and its correlation with efficacy: exploratory analysis of the ZGDH3 study.2025European journal of medical researchRCTFree full text
  2. Preoperative Diagnosis of Dual-Phenotype Hepatocellular Carcinoma Using Enhanced MRI Radiomics Models.2023Journal of magnetic resonance imaging : JMRIRCT
  3. Lactylation-driven MVP upregulation boosts immunotherapy resistance by inhibiting PD-L1 degradation in hepatocellular carcinoma.2025Journal for immunotherapy of cancerFree full text
  4. Which risk model can better predict hepatocellular carcinoma in hepatitis B patients with an antiviral treatment duration of over 1 year?2024Journal of hepatology
  5. cFUT8 promotes liver cancer progression by miR-548c/FUT8 axis.2021Signal transduction and targeted therapyFree full text
Trials on ClinicalTrials.gov6
  1. Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.RecruitingNCT05862337Study sitePhase 3Start 2023-05
  2. Evaluate the Effect of Tirazamine on Primary Liver Cancer.TerminatedNCT06848556Study sitePhase 1/Phase 2Start 2021-05
  3. Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)TerminatedNCT04246177Study sitePhase 3Start 2020-05
  4. To Evaluate the Safety and Efficacy of Microwave Ablation Therapy in Patients With Primary Liver CancerTerminatedNCT04520906Study siteN/AStart 2020-12
  5. A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular CarcinomaActive, not recruitingNCT04194775Study sitePhase 3Start 2019-12
  6. Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)CompletedNCT03062358Study sitePhase 3Start 2017-04

PubMed searchClinicalTrials.gov

Stomach cancer

胃癌
1.8%Leads about 1 in 54 of China's research papers on Stomach cancer

Led 180 of 9,782 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (3.9%).

Run this PubMed search

Open trials led
3
Research papers it led
180
Trials it led
5
Share of China's trials
0.3%
Share of the world's papers
0.9%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025
ThemesPeritoneal spread & advanced diseaseSurgeryImaging & AI

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. First Affiliated Hospital of Soochow University90
  2. Second Affiliated Hospital of Soochow University32
  3. Third Affiliated Hospital of Soochow University25
  4. Changshu Hospital, Soochow University Counted in the group total10
  5. Changzhou Tumor Hospital, Soochow University4
  6. Fourth Affiliated Hospital of Soochow University Counted in the group total3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Combined sleep intervention and nutritional support to enhance postoperative recovery in gastric cancer: a prospective randomized controlled trial.2026Surgical endoscopyRCT
  2. Integrating narrative therapy and sleep intervention to enhance recovery, nutritional reconstitution, and 24-month survival following curative gastrectomy: a randomized controlled trial.2026Journal of cancer survivorship : research and practiceRCT
  3. Psychosocial intervention to improve sleep, psychological adjustment, and quality of life in gastric cancer patients undergoing gastrectomy: a randomized controlled trial.2026Journal of cancer survivorship : research and practiceRCT
  4. Combined Effects of Psychological Intervention and Enhanced Nutritional Support on Postoperative Recovery in Gastric Cancer Patients.2026Nutrition and cancerRCT
  5. Enhancing short-term recovery after gastric cancer surgery: an information-motivation-behavioral skills (IMB) model with nutritional support.2025Future oncology (London, England)RCTFree full text
Trials on ClinicalTrials.gov6
  1. AI Model for Early Gastric Cancer Diagnosis Using Endoscopic ImagingRecruitingNCT07551466Lead sponsorStart 2026-05
  2. Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid MutationsRecruitingNCT07012447Lead sponsorPhase 2Start 2025-04
  3. Efficacy and Safety of Sintilimab Combined With Nab-paclitaxel and Tegio (aTS) as First-line Treatment of Unresectable Locally Advanced, Recurrent or Metastatic Adenocarcinoma of Gastric and Gastroesophageal Junction,a Phase II Clinical StudyNot yet recruitingNCT06241469Lead sponsorPhase 2Start 2024-02
  4. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07385703Study sitePhase 3Start 2026-04
  5. Lymph Node Dissection After Neoadjuvant Therapy for Gastric and EGJ AdenocarcinomaNot yet recruitingNCT07902596Study siteStart 2026-10
  6. Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric CancerRecruitingNCT07552402Study siteN/AStart 2026-06

PubMed searchClinicalTrials.gov

Retinoblastoma

视网膜母细胞瘤
1.7%Leads about 1 in 60 of China's research papers on Retinoblastoma ▲ from 0.4%

Led 5 of 301 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.0%).

Run this PubMed search

Open trials led
0
Research papers it led
5
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 1120242025: 222025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. First Affiliated Hospital of Soochow University2
  2. Children Hospital, Soochow University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Chordoma

脊索瘤
1.9%Leads about 1 in 53 of China's research papers on Chordoma New since 2021

Led 2 of 105 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.8%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 002025

Hospitals counted here

  1. First Affiliated Hospital of Soochow University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Osteosarcoma

骨肉瘤
1.0%Leads about 1 in 98 of China's research papers on Osteosarcoma ▼ from 1.7%

Led 23 of 2,257 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
23
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 332025

Over half of these papers are lab or animal studies.

PubMed searchClinicalTrials.gov

Gastrointestinal stromal tumour

胃肠道间质瘤
4.2%Leads about 1 in 24 of China's research papers on Gastrointestinal stromal tumour ▲ from 0.5%

Led 22 of 523 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.3%).

Run this PubMed search

Open trials led
0
Research papers it led
22
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
1.3%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 442025

PubMed searchClinicalTrials.gov

Neuroblastoma

神经母细胞瘤
1.7%Leads about 1 in 60 of China's research papers on Neuroblastoma

Led 19 of 1,132 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.8%).

Run this PubMed search

Open trials led
0
Research papers it led
19
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 332025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Children's Hospital of Soochow University16
  2. Third Affiliated Hospital of Soochow University1
  3. First Affiliated Hospital of Soochow University1
  4. Dushu Lake Hospital, Soochow University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Ewing sarcoma

尤文肉瘤
1.2%Leads about 1 in 81 of China's research papers on Ewing sarcoma

Led 2 of 163 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.6%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025

Hospitals counted here

  1. Children's Hospital of Soochow University1
  2. Second Affiliated Hospital of Soochow University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Multiple myeloma

多发性骨髓瘤
2.3%Leads about 1 in 44 of China's research papers on Myeloma

Led 38 of 1,676 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.8%).

Run this PubMed search

Open trials led
7
Research papers it led
38
Trials it led
22
Share of China's trials
4.5%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 442025
ThemesDiagnosis, MRD & riskDrug combinationsStem cell transplant

Hospitals counted here

  1. First Affiliated Hospital of Soochow University27
  2. Third Affiliated Hospital of Soochow University3
  3. Second Affiliated Hospital of Soochow University2
  4. Dushu Lake Hospital, Soochow University Counted in the group total1
  5. Affiliated Hospital of Soochow University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma.2024The New England journal of medicineRCT
  2. Effect of oral care models on the prevention of oral mucositis induced by high-doses of melphalan in patients undergoing ASCT.2025MedicineFree full text
  3. Application of individualized low-protein diet nursing for managing multiple myeloma patients with renal impairment.2025MedicineFree full text
  4. A 2D-STI echocardiographic diagnostic model established for cardiac amyloidosis complicated with multiple myeloma.2025International journal of cardiology
  5. A rare case of concurrent JAK2V617F-positive essential thrombocythemia, multiple myeloma, and colorectal adenocarcinoma.2025Indian journal of pathology & microbiology
Trials on ClinicalTrials.gov6
  1. A Single-center, Prospective, Single-arm Clinical Study Exploring the Treatment of Newly Diagnosed Multiple Myeloma Patients With t(11;14) Suitable for Transplantation Using the SonKRd RegimenNot yet recruitingNCT07709884Lead sponsorPhase 4Start 2026-07
  2. Safety and Efficacy of RN1201 Injection as First-Line Treatment for Newly Diagnosed Multiple MyelomaRecruitingNCT07652138Lead sponsorPhase 1Start 2025-07
  3. A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell LeukemiaRecruitingNCT06730256Lead sponsorEarly phase 1Start 2025-07
  4. Conversion to Carfilzomib Therapy in Bortezomib Intolerant Newly Diagnosed Multiple Myeloma(NDMM) PatientsRecruitingNCT06682156Lead sponsorStart 2024-09
  5. Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease DetectionRecruitingNCT06409702Lead sponsorPhase 4Start 2024-06
  6. Comparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma PatientsRecruitingNCT04025450Lead sponsorPhase 1/Phase 2Start 2019-07

PubMed searchClinicalTrials.gov

B-cell acute lymphoblastic leukaemia (B-ALL)

B 细胞急性淋巴细胞白血病
6.7%Leads about 1 in 15 of China's research papers on B-ALL ▲ from 2.9%

Led 15 of 225 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.9%).

Run this PubMed search

Open trials led
10
Research papers it led
15
Trials it led
19
Share of China's trials
7.5%
Share of the world's papers
1.4%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 552025
ThemesChildrenCAR-T & cell therapyAntibody & targeted drugs

Hospitals counted here

  1. First Affiliated Hospital of Soochow University12
  2. Children's Hospital of Soochow University3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Low-dose glucocorticoid improves progression-free survival of children with B cell acute lymphoblastic leukaemia following chimeric antigen receptor T-cell therapy.2025Frontiers in immunologyFree full text
  2. A phase 2 trial of a "sandwich" strategy: Sequential CD22/CD19 chimeric antigen receptor T-cells therapy combined with autologous hematopoietic stem cell transplantation in patients with Philadelphia chromosome-negative 2025CancerFree full text
  3. Frequent TCR rearrangements in pediatric B-cell lymphoblastic acute leukemia: genomic and phenotypic features.2025Annals of hematologyFree full text
  4. Frontline therapy combining with intrathecal dexamethasone effectively alleviate immune effector cell-associated neurotoxicity syndrome in pediatric relapsed B-ALL receiving pCAR-19B-cases report.2025BMC pediatricsFree full text
  5. Shorter Duration of Blinatumomab Administration to 14 Days Has Same Efficacy and Safety Profile in Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: A Retrospective Single-Center Study.2025Acta haematologica
Trials on ClinicalTrials.gov6
  1. U96-CAR-T-Cells For R/R B-ALLNot yet recruitingNCT07511426Lead sponsorPhase 1Start 2026-07
  2. BEBT-908 in MEF2D-Rearranged Relapsed/Refractory or MRD-Positive B-Cell Precursor Acute Lymphoblastic LeukemiaRecruitingNCT07854652Lead sponsorPhase 1Start 2026-09
  3. Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline ChemotherapyRecruitingNCT06985485Lead sponsorPhase 2Start 2025-05
  4. Full-course Immunotherapy Combined With Chemotherapy in Newly Diagnosed B-cell Acute Lymphoblastic LeukemiaRecruitingNCT07564453Lead sponsorPhase 2Start 2025-04
  5. Hema-NeoTIL01 Cell Infusion Therapy in Relapsed/Refractory Acute LeukemiaNot yet recruitingNCT06559644Lead sponsorEarly phase 1Start 2024-09
  6. Blinatumomab and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALLRecruitingNCT06507514Lead sponsorPhase 1Start 2024-04

PubMed searchClinicalTrials.gov

Aplastic anaemia

再生障碍性贫血
3.6%Leads about 1 in 27 of China's research papers on Aplastic anaemia

Led 15 of 412 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (17.2%).

Run this PubMed search

Open trials led
2
Research papers it led
15
Trials it led
3
Share of China's trials
3.1%
Share of the world's papers
0.9%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 3320242025: 222025
ThemesStem cell transplantChildrenImmunosuppressive treatment

Hospitals counted here

  1. First Affiliated Hospital of Soochow University11
  2. Children's Hospital of Soochow University4

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Haemophagocytic lymphohistiocytosis (HLH)

噬血细胞性淋巴组织细胞增生症
3.0%Leads about 1 in 33 of China's research papers on HLH ▲ from 1.6%

Led 12 of 399 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (22.3%).

Run this PubMed search

Open trials led
2
Research papers it led
12
Trials it led
3
Share of China's trials
6.2%
Share of the world's papers
0.7%
Papers led per year
2021: 0020212022: 0020222023: 3320232024: 1120242025: 112025
ThemesEBV & infection triggersTreatment regimensChildren

Hospitals counted here

  1. First Affiliated Hospital of Soochow University6
  2. Children's Hospital of Soochow University5
  3. Third Affiliated Hospital of Soochow University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Haemophilia A

血友病 A
2.6%Leads about 1 in 39 of China's research papers on Haemophilia A ▲ from 0.7%

Led 7 of 272 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (15.8%).

Run this PubMed search

Open trials led
0
Research papers it led
7
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 1120242025: 222025

Hospitals counted here

  1. First Affiliated Hospital of Soochow University6
  2. Fourth Affiliated Hospital of Soochow University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. No Benefit to Platelet-rich Plasma Over Placebo Injections in Terms of Pain or Function in Patients with Hemophilic Knee Arthritis: A Randomized Trial.2022Clinical orthopaedics and related researchRCT
  2. Incidence of deep venous thrombosis in patients with hemophilia undergoing bilateral simultaneous total knee arthroplasty: a retrospective cohort study.2024BMC musculoskeletal disorders
  3. Hybridization capture long-read sequencing and de novo assembly of homologous haplotypes: a comprehensive hemophilia test.2025Blood advances
  4. Macrophage membrane-encapsulated miRNA nanodelivery system for the treatment of hemophilic arthritis.2025Journal of controlled release : official journal of the Controlled Release Society
  5. Safety and efficacy of an anti-human APC antibody for prophylaxis of congenital factor deficiencies in preclinical models.2023Blood
Trials on ClinicalTrials.gov6
  1. Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy DrugsRecruitingNCT06111638Study sitePhase 2/Phase 3Start 2024-01
  2. A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia ACompletedNCT05707351Study sitePhase 3Start 2023-03
  3. Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion ProteinCompletedNCT06142552Study sitePhase 3Start 2023-12
  4. Efficacy and Safety of Turoctocog Alfa Pegol (N8-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A (pathfinder10)CompletedNCT05082116Study sitePhase 3Start 2021-09
  5. A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without InhibitorsCompletedNCT05053139Study sitePhase 3Start 2021-12
  6. A Post Approval Commitment Study to Gain More Information on How Safe and Effective KOVALTRY is in Chinese Children, Adolescents /Adults With Severe Hemophilia ACompletedNCT04565236Study sitePhase 4Start 2020-09

PubMed searchClinicalTrials.gov

Thrombotic thrombocytopenic purpura

血栓性血小板减少性紫癜
7.8%Leads about 1 in 13 of China's research papers on Thrombotic thrombocytopenic purpura ▲ from 4.3%

Led 5 of 64 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.4%).

Run this PubMed search

Open trials led
1
Research papers it led
5
Trials it led
1
Share of China's trials
16.7%
Share of the world's papers
0.7%
Papers led per year
2021: 1120212022: 2220222023: 2220232024: 0020242025: 002025

Hospitals counted here

  1. First Affiliated Hospital of Soochow University5

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Neuromyelitis optica spectrum disorder (NMOSD)

视神经脊髓炎谱系疾病
2.5%Leads about 1 in 40 of China's research papers on NMOSD ▲ from 0.7%

Led 12 of 485 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.5%).

Run this PubMed search

Open trials led
0
Research papers it led
12
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.6%
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 1120242025: 222025
ThemesBiologic drugsRelapse preventionImaging

Hospitals counted here

  1. First Affiliated Hospital of Soochow University10
  2. Second Affiliated Hospital of Soochow University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Myasthenia gravis

重症肌无力
1.8%Leads about 1 in 56 of China's research papers on Myasthenia gravis ▲ from 0.4%

Led 9 of 499 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.6%).

Run this PubMed search

Open trials led
0
Research papers it led
9
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 1120242025: 112025
ThemesAntibodies & diagnosisBiologic & complement drugsStandard immunotherapy

Hospitals counted here

  1. First Affiliated Hospital of Soochow University9

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Moyamoya disease

烟雾病
1.1%Leads about 1 in 89 of China's research papers on Moyamoya ▼ from 1.8%

Led 4 of 356 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (19.9%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 2220242025: 002025
ThemesRevascularisation surgeryImaging & blood flowChildren

Hospitals counted here

  1. First Affiliated Hospital of Soochow University3
  2. Changshu First People's Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Wilson disease

肝豆状核变性(Wilson 病)
1.0%Leads about 1 in 100 of China's research papers on Wilson disease

Led 2 of 201 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (7.5%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 002025
ThemesGenetics (ATP7B)Liver disease & transplant

Hospitals counted here

  1. First Affiliated Hospital of Soochow University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎
0.0%Leads none of China's research papers on Anti-NMDA receptor encephalitis

Led 0 of 264 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.2%).

Run this PubMed search

Open trials led
1
Research papers it led
0
Trials it led
1
Share of China's trials
16.7%
Share of the world's papers
0.0%

PubMed searchClinicalTrials.gov

Idiopathic pulmonary fibrosis

特发性肺纤维化
0.7%Leads under 1 in 100 of China's research papers on Idiopathic pulmonary fibrosis New since 2021

Led 7 of 989 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
7
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 332025

Hospitals counted here

  1. First Affiliated Hospital of Soochow University3
  2. Third Affiliated Hospital of Soochow University2
  3. Taicang Hospital, Affiliated With Soochow University1
  4. Fourth Affiliated Hospital of Soochow University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症
0.3%Leads under 1 in 100 of China's research papers on Amyotrophic lateral sclerosis New since 2021

Led 2 of 779 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.3%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.03%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 002025

Hospitals counted here

  1. First Affiliated Hospital of Soochow University1
  2. Third Affiliated Hospital of Soochow University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Fabry disease

法布雷病
5.5%Leads about 1 in 18 of China's research papers on Fabry disease

Led 4 of 73 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.3%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 222025

Hospitals counted here

  1. First Affiliated Hospital of Soochow University3
  2. Fourth Affiliated Hospital of Soochow University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Duchenne muscular dystrophy

杜氏肌营养不良
0.9%Leads under 1 in 100 of China's research papers on Duchenne muscular dystrophy

Led 2 of 213 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.8%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.08%
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 0020242025: 002025

Hospitals counted here

  1. First Affiliated Hospital of Soochow University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Behçet disease

白塞病
0.4%Leads under 1 in 100 of China's research papers on Behçet disease New since 2021

Led 1 of 245 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (22.9%).

Run this PubMed search

Open trials led
0
Research papers it led
1
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.08%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

Hospitals counted here

  1. Second Affiliated Hospital of Soochow University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

IgA nephropathy

IgA 肾病
0.9%Leads under 1 in 100 of China's research papers on IgA nephropathy

Led 7 of 736 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.4%).

Run this PubMed search

Open trials led
0
Research papers it led
7
Trials it led
2
Share of China's trials
1.7%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 2220222023: 1120232024: 2220242025: 002025

PubMed searchClinicalTrials.gov

Osteogenesis imperfecta

成骨不全症
1.0%Leads about 1 in 99 of China's research papers on Osteogenesis imperfecta New since 2021

Led 1 of 99 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (17.2%).

Run this PubMed search

Open trials led
0
Research papers it led
1
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

Hospitals counted here

  1. Children's Hospital of Soochow University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Primary biliary cholangitis

原发性胆汁性胆管炎
1.0%Leads about 1 in 100 of China's research papers on Primary biliary cholangitis New since 2021

Led 3 of 300 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.0%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 0020242025: 002025

Hospitals counted here

  1. First Affiliated Hospital of Soochow University2
  2. Affiliated Zhangjiagang Hospital of Soochow University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Primary sclerosing cholangitis

原发性硬化性胆管炎
2.0%Leads about 1 in 50 of China's research papers on Primary sclerosing cholangitis New since 2021

Led 2 of 100 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (7.0%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 002025

Hospitals counted here

  1. Third Affiliated Hospital of Soochow University1
  2. First Affiliated Hospital of Soochow University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Hirschsprung disease

先天性巨结肠
1.9%Leads about 1 in 54 of China's research papers on Hirschsprung disease

Led 3 of 161 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (13.0%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 2220212022: 1120222023: 0020232024: 0020242025: 002025

Hospitals counted here

  1. Children's Hospital of Soochow University3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov